Physician profile
Shoaib Ashraf
NPI 1508424466
$2,195.82
in general payments reported to CMS, 2019-2025
14 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $631 · 2024: $829 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529 · Education: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.61 |
| Education | $667.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $888.25 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Ensite, Jot Dx |
| Aop Health US, LLC | $515.87 | 2025 | Rapiblyk |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.53 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $165.37 | 2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $68.70 | 2024-2025 | |
| Biotronik INC. | $64.80 | 2023-2024 | Biomonitor, Acticor 7 Vr-T Dx |
| Boston Scientific Corporation | $56.34 | 2023-2024 | |
| Medtronic, INC. | $49.67 | 2023-2024 | Mycarelink, Azure Xt Dr Mri Surescan |
| Abiomed | $48.58 | 2025 | |
| Janssen Pharmaceuticals, INC | $44.69 | 2024 | Xarelto |
| Lantheus Medical Imaging, INC. | $28.51 | 2024 | |
| Daiichi Sankyo INC. | $26.45 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $23.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $23.50 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shoaib Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.